Steven C. Kao

Camperdown, NSW 2050, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy.

Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 07, 2025

Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.

Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.

Journal: Cell reports. Medicine

Published: December 26, 2023

PEMMELA: a promising regimen at the expense of toxicity.

PEMMELA: a promising regimen at the expense of toxicity.

Journal: The Lancet. Oncology

Published: September 25, 2023

Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations.

Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations.

Journal: Immunotherapy

Published: June 11, 2021

Emerging biological therapies for the treatment of malignant pleural mesothelioma.

Emerging biological therapies for the treatment of malignant pleural mesothelioma.

Journal: Expert opinion on emerging drugs

Published: May 04, 2021

COVID-19: the use of immunotherapy in metastatic lung cancer.

COVID-19: the use of immunotherapy in metastatic lung cancer.

Journal: Immunotherapy

Published: May 01, 2020

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.

Journal: The Lancet. Oncology

Published: February 22, 2020

Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.

Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 14, 2019

Why do delays to diagnosis and treatment of lung cancer occur? A mixed methods study of insights from Australian clinicians.

Why do delays to diagnosis and treatment of lung cancer occur? A mixed methods study of insights from Australian clinicians.

Journal: Asia-Pacific journal of clinical oncology

Published: August 28, 2019

Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists.

Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists.

Journal: Journal of clinical medicine

Published: July 20, 2018

An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.

An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.

Journal: Journal of clinical medicine

Published: May 17, 2018

Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms.

Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms.

Journal: Journal of clinical medicine

Published: May 04, 2018

Showing 1-12 of 19

Last Updated: 09/26/2026